Home LATEST NEWS Encouraging Data for Third Dose of Moderna’s Vaccine Against Omicron | ...

Encouraging Data for Third Dose of Moderna’s Vaccine Against Omicron | Coronavirus


In a statement released Monday morning, the US pharmaceutical said that a dose of 50 micrograms of its vaccine – the one already approved by Health Canada – multiplies by about 37 the amount of neutralizing antibodies made by the human body, 29 days after its reception.

A 100 microgram dose of the same vaccine does even better. It increases the amount of antibodies in the body of a person who has received two doses about 83 times the same period of just over four weeks after their injection.

Moderna’s data comes from tests carried out on blood samples contaminated with a pseudovirus mimicking the Omicron variant in the laboratories of the National Institute of Allergy and Infectious Diseases Vacccine Research Center, at Duke University Medical Center.

It is very effective and very safe. I believe it will protect people for the holiday season and for the winter months when the pressure from Omicron is greatest.

A quote from Paul Burton, Chief Medical Officer of Moderna

Qualified as reassuring by Moderna boss Stéphane Bancel, this data has yet to be peer reviewed. The company says it is preparing to submit a first version of its analysis to a scientific publication.

Recent tests by the United States National Institutes of Health, however, have come to similar conclusions. Tests from Pfizer also showed that a booster dose of its COVID-19 vaccine produced a comparable jump in antibodies against the Omicron variant.

Moderna further maintains that a phase 2/3 study conducted for its booster dose of 100 micrograms found it to be safe and well tolerated by participants, although the side effects were slightly more common than for a third dose of 50 micrograms.

Considering these results, Moderna says the booster doses of its current vaccine will be the first line of defense against the Omicron variant. She will still develop a booster dose in parallel to specifically tackle this variant, in case it is necessary, she specifies.

Clinical trials for this specific booster dose are expected to begin in early 2022, she said.

The evolution of COVID-19 from hour to hour.
Previous articleOmicron: Israel places eight countries, including Canada, on red list | Coronavirus
Next articleTyphoon Rai kills at least 375 in Philippines